Article

Apolipoprotein E genotype and the risk of recurrent lobar intracerebral hemorrhage

Department of Neurology, Massachusetts General Hospital and Harvard Medical School, Boston 02114, USA.
New England Journal of Medicine (Impact Factor: 54.42). 02/2000; 342(4):240-5. DOI: 10.1056/NEJM200001273420403
Source: PubMed

ABSTRACT Recurrent lobar intracerebral hemorrhage is the hallmark of cerebral amyloid angiopathy. The factors that predispose patients to early recurrence of lobar hemorrhage are unknown. One candidate is the apolipoprotein E gene, since both the epsilon2 and the epsilon4 alleles of apolipoprotein E appear to be associated with the severity of amyloid angiopathy.
We performed a prospective, longitudinal study of consecutive elderly patients who survived a lobar intracerebral hemorrhage. The patients were followed for recurrent hemorrhagic stroke by interviews at six-month intervals and reviews of medical records and computed tomographic scans.
Nineteen of 71 enrolled patients had recurrent hemorrhages during a mean follow-up period of 23.9+/-14.8 months, yielding a 2-year cumulative rate of recurrence of 21 percent. The apolipoprotein E genotype was significantly associated with the risk of recurrence. Carriers of the epsilon2 or epsilon4 allele had a two-year rate of recurrence of 28 percent, as compared with only 10 percent for patients with the common apolipoprotein E epsilon3/epsilon3 genotype (risk ratio, 3.8; 95 percent confidence interval, 1.2 to 11.6; P=0.01). Early recurrence occurred in eight patients, four of whom had the uncommon epsilon2/epsilon4 genotype. Also at increased risk for recurrence were patients with a history of hemorrhagic stroke before entry into the study (two-year recurrence, 61 percent; risk ratio, 6.4; 95 percent confidence interval, 2.2 to 18.5; P<0.001).
The apolipoprotein E genotype can identify patients with lobar intracerebral hemorrhage who are at highest risk for early recurrence. This finding makes possible both the provision of prognostic information to patients with lobar hemorrhage and a method of targeting and assessing potential strategies for prevention.

Download full-text

Full-text

Available from: Heather C O'Donnell, Aug 02, 2015
0 Followers
 · 
105 Views
  • Source
    • "Hemorrhages in locations characteristic of hypertensive vasculopathy, such as basal ganglia, thalamus, or brainstem also recur, but less frequently [8]. Other factors associated with P-ICH recurrence include age [4], absence of anti-platelet medication after stroke [9], previous hemorrhage before the presenting P-ICH [7], possession of the apolipoprotein E␧2 or ␧4 alleles [7] [10], and a greater number of microbleeds by T2- weighted gradient-echo magnetic resonance imaging (MRI) [11]. Furthermore, use of post-ICH anticoagulant was reported to triple the risk of a hemorrhagic event [4]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: OBJECTIVE: The study examined differences in the recurrence rate of primary intracerebral hemorrhage (P-ICH) according to anti-hypertensive drug (AHD) use by patients with hypertension. METHODS: This prospective, longitudinal cohort study was performed on 2384 patients diagnosed with supratentorial P-ICH and hypertension in the stroke unit of a single-center. During follow-up (mean, 44.9±31.5 months), investigators interviewed subjects or caregivers by telephone or examined patients every 3-6 months. Target blood pressure was <140/90mmHg in the P-ICH cohort with hypertension. RESULTS: Of 1317 P-ICH patients defined to be taking AHDs, P-ICH recurrence occurred in 129 (9.8%). 1211 patients (92.0%) reached target blood pressure. In multivariate regression analysis, advanced age (≥70 years), poor functional outcome after first P-ICH, lobar location of P-ICH, previous history of cerebral ischemia, diuretic monotherapy and α- or β-blocker monotherapy were associated with risk of recurrence. CONCLUSIONS: Although hypertension is the most important factor for preventing P-ICH recurrence, we found that, even in the presence of optimal anti-hypertensive medication, recurrent P-ICH attack can occur. Therefore, management of other risk factors of recurrent P-ICH, such as modification of lifestyle, must be considered in treating the P-ICH patients.
    Clinical neurology and neurosurgery 08/2012; 115(5). DOI:10.1016/j.clineuro.2012.07.010 · 1.25 Impact Factor
  • Source
    • "Conversely, the yearly risk of hypertensive ICH recurrence is approximately 2% [Bailey et al. 2001] whereas that due to amyloid angiopathy ranges from 5% to 15%, depending on genetic predisposition [O&apos;Donnell et al. 2000]. While risk of ICH recurrence does not appear to be increased by aspirin [Viswanathan et al. 2006], the risk may be tripled by warfarin [Vermeer et al. 2002]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Intracerebral hemorrhage (ICH) represents 10-15% of all cerebrovascular events, and is associated with substantial morbidity and mortality. In contrast to ischemic cerebrovascular disease in which acute therapies have proven beneficial, ICH remains a more elusive condition to treat, and no surgical procedure has proven to be beneficial. Aspects pertinent to medical ICH management include cessation or minimization of hematoma enlargement, prevention of intraventricular extension, and treatment of edema and mass effect. Therapies focusing on these aspects include prothrombotic (hemostatic) agents, antihypertensive strategies, and antiedema therapies. Therapies directed towards the reversal of antithrombosis caused by antiplatelet and anticoagulant agents are frequently based on limited data, allowing for diverse opinions and practice styles. Several newer anticoagulants that act by direct thrombin or factor Xa inhibition have no natural antidote, and are being increasingly used for various prophylactic and therapeutic indications. As such, these new anticoagulants will inevitably pose major challenges in the treatment of patients with ICH. Ongoing issues in the management of patients with ICH include the need for effective treatments that not only limit hematoma expansion but also result in improved clinical outcomes, the identification of patients at greatest risk for continued hemorrhage who may most benefit from treatment, and the initiation of therapies during the hyperacute period of most active hemorrhage. Defining hematoma volume increases at various anatomical locations that translate into clinically meaningful outcomes will also aid in directing future trials for this disease. The focus of this review is to underline and discuss the various controversies and challenges involved in the medical management of patients with primary and antithrombotic-related ICH.
    Therapeutic Advances in Neurological Disorders 01/2012; 5(1):43-56. DOI:10.1177/1756285611422267
  • Source
    • "Unfortunately, despite a number of preclinical studies reporting positive results, no drugs have been translated into human treatments (Badjatia & Rosand, 2005). An important concern is that ICH is mainly a disease of the elderly (Collins et al., 2003), in whom there are increases in the major predisposing factors: chronic hypertension and amyloid angiopathy (O'Donnell et al., 2000; Ariesen et al., 2003). Despite this, experimental models have almost exclusively used young animals. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Intracerebral hemorrhage (ICH) usually affects older humans but almost no experimental studies have assessed aged animals. We address how aging alters inflammation, neuron death and lesion resolution after a hemorrhage in the rat striatum. In the normal aged brain, microglia displayed a 'dystrophic' phenotype, with shorter cellular processes and large gaps between adjacent cells, and there was more astrocyte reactivity. The ICH injury was monitored as hematoma volume and number of dying neurons at 1 and 3 days, and the volume of the residual lesion, ventricles and lost tissue at 28 days. Inflammation at 1 and 3 days was assessed from densities of microglia with resting vs. activated morphologies, or expressing the lysosomal marker ED1. Despite an initial delay in neuron death in aged animals, by 28 days, there was no difference in neuron density or volume of tissue lost. However, lesion resolution was impaired in aged animals and there was less compensatory ventricular expansion. At 1 day after ICH, there were fewer activated microglia/macrophages in the aged brain, but by 3 days there were more of these cells at the edge of the hematoma and in the surrounding parenchyma. In both age groups a glial limitans had developed by 3 days, but astrocyte reactivity and the spread of activated microglia/macrophages into the surrounding parenchyma was greater in the aged. These findings have important implications for efforts to reduce secondary injury after ICH and to develop anti-inflammatory therapies to treat ICH in aged humans.
    European Journal of Neuroscience 11/2008; 28(7):1316-28. DOI:10.1111/j.1460-9568.2008.06442.x · 3.67 Impact Factor
Show more